Antibody Discovery Market by Type of Service Offered (Antigen Designing, Hit Generation, Lead Selection, Lead Optimization and Lead Characterization), Antibody Discovery Method (Hybridoma based, Library based, Single Cell based and Transgenic Animal based

Antibody Discovery Market by Type of Service Offered (Antigen Designing, Hit Generation, Lead Selection, Lead Optimization and Lead Characterization), Antibody Discovery Method (Hybridoma based, Library based, Single Cell based and Transgenic Animal based), Type of Antibody Generated (Monoclonal Antibodies, Bispecific Antibodies and Others), Nature of Antibody Generated (Chimeric, Human, Humanized and Murine), Type of Therapeutic Areas (Cardiovascular Disorders, Immunological Disorders, Infectious Disorders, Neurological Disorders, Oncological Disorders and Others) and Key Geographies (North America, Europe, Asia, Latin America, Middle East and North Africa and Rest of the World): Industry Trends and Global Forecasts, Till 2035

ANTIBODY DISCOVERY MARKET: OVERVIEW

As per Roots Analysis, the global antibody discovery market is estimated to grow from USD 1.6 billion in the current year to USD 6.3 billion by 2035, at a CAGR of 12% during the forecast period, till 2035.

The market sizing and opportunity analysis has been segmented across the following parameters:

Type of Service Offered

Antigen Designing

Hit Generation

Lead Selection

Lead Optimization

Lead Characterization

Antibody Discovery Method

Hybridoma based

Library based

Single Cell based

Transgenic Animal based

Type of Antibody Generated

Monoclonal Antibodies

Bispecific Antibodies

Others

Nature of Antibody Generated

Chimeric

Human

Humanized

Murine

Type of Therapeutic Areas

Cardiovascular Disorders

Immunological Disorders

Infectious Disorders

Neurological Disorders

Oncological Disorders

Others

Key Geographical Regions

North America

Europe

Asia

Latin America

Middle East and North Africa

Rest of the World

ANTIBODY DISCOVERY MARKET: GROWTH AND TRENDS

Owing to several beneficial features, such as high specificity, and a favorable safety profile, antibodies have emerged as a promising alternative, particularly for the treatment of cancer, autoimmune diseases, and infectious diseases. It is worth highlighting that, at present, antibodies represent the largest class of biologics, with 79 molecules approved till date and over 200 molecules in the preclinical / discovery stages. This demonstrates the extensive development efforts being undertaken by stakeholders in this domain.

Given the complexities of modern drug development, several companies prefer to outsource as a strategic solution to optimize their research efforts. This expected shift can be attributed to various reasons, such as reduced timelines, lessened financial risks associated with failed trials and accelerated workflows. At present, over 160 players are offering a wide array of antibody discovery services.

As drug developers invest and investigate more in these innovative therapies, the market for antibody discovery is anticipated to expand further in the coming decade. Driven by the rising demand for antibody-based therapeutics and increasing preference for outsourcing, the opportunity for antibody discovery services and platforms is likely to increase at a significant growth rate in the foreseen future.

ANTIBODY DISCOVERY MARKET: KEY INSIGHTS

The report delves into the current state of the antibody discovery market and identifies potential growth opportunities within the industry. Some key findings from the report include:

1. More than 160 players, present across the globe, claim to offer customized services to support antibody drug discovery operations; nearly 90% of these players offer the capability to provide hit generation services.

2. The market landscape is highly fragmented, featuring the presence of both new entrants and established players based across different geographical regions; close to 40% of such players are small companies.

3. In pursuit of building a competitive edge, service providers are actively upgrading their existing capabilities and adding new competencies in order to augment their respective portfolios and affiliated offerings.

4. Close to 300 antibody discovery technologies are currently available in the market, which can be utilized by antibody drug developers to conduct various types of antibody discovery operations.

5. Over 75% of the platform providers claim to offer technologies for the discovery of monoclonal antibodies; the majority of such players use mouse as their primary animal model to generate these antibodies.

6. Platform providers are focusing on the integration of advanced features into their respective platforms in order to augment their antibody discovery portfolios.

7. In recent years, the domain has witnessed a steady growth in partnership activity; majority of the initiatives have been product development / commercialization agreements, carried out by players based in North America.

8. Considering the lucrative opportunities associated with antibody discovery domain, investors have actively disbursed funds, primarily in the players based in North America.

9. In recent years, there has been a significant increase in the number of out-licensing deals and the upfront and conditional payments received by the antibody discovery technology developers.

10. The antibody discovery services market is likely to grow at a CAGR of ~12% over the next 11 years, primarily driven by the revenues generated from hit generation services offered by the players in this domain.

11. In the long term, the antibody discovery platforms developed for monoclonal antibodies are likely to emerge as the key growth drivers of the market; Asia Pacific is anticipated to be the fastest growing region.

ANTIBODY DISCOVERY MARKET: KEY SEGMENTS

Lead Selection Segment is the Fastest Growing Segment in the Antibody Discovery Services Market

Based on the type of service offered, the market is segmented into antigen designing, hit generation, lead selection, lead optimization, and lead characterization. It is worth highlighting that the majority of the current antibody discovery services market is captured by hit generation segment. This can be attributed to the fact that hit generation is a critical step that involves rigorous screening of a diverse pool of antibodies to extract leads with the highest affinity and specificity for a target. Therefore, the major proportion of the R&D expenditure for antibody discovery projects is spent on the hit generation step of antibody discovery.

Hybridoma Method is Likely to Dominate the Antibody Discovery Services Market During the Forecast Period

Based on the antibody discovery method, the market is segmented into hybridoma based method, library based method, single cell based method and transgenic animal based method. It is worth highlighting that the antibody discovery services market for single cell-based methods is likely to grow at a relatively higher CAGR, during the forecast period.

By Type of Antibody Generated, the Antibody Discovery Services Market is Currently Dominated by Monoclonal Antibodies

Based on the type of antibody generated, the market is segmented into monoclonal antibodies, bispecific antibodies and others. It is worth highlighting that bispecific antibody is likely to grow at a relatively higher CAGR as compared to monoclonal antibodies, during the forecast period.

Human Antibodies Segment is Likely to Dominate the Antibody Discovery Services Market During the Forecast Period

Based on the nature of the antibody generated, the market is segmented into chimeric antibodies, human antibodies, humanized antibodies and murine antibodies. It is worth highlighting that the human antibodies segment is likely to grow at a relatively higher CAGR, during the forecast period. This can be attributed to the several benefits of human antibodies, which include reduced immunogenicity and the increased serum half-life of the monoclonal antibodies in humans.

Oncological Disorders Segment Accounts for the Largest Share for the Antibody Discovery Services Market

Based on therapeutic area, the market is segmented into cardiovascular disorders, immunological disorders, infectious disorders, neurological disorders, oncological disorders and others. While oncological disorders account for a relatively higher market share, it is worth highlighting that the cardiovascular disorders segment is expected to witness substantial market growth in the coming years.

North America Accounts for the Largest Share of the Market

Based on key geographical regions, the market is segmented into North America, Europe, Asia, Latin America, Middle East and North Africa, and Rest of the World. It is worth highlighting that over the years, the market in the Middle East and North Africa is expected to grow at a higher CAGR.

Example Players in the Antibody Discovery Market

Ablexis

Antibody Solutions

ChemPartner

Creative Biolabs

GenScript

Genmab

Harbour BioMed

ImmunoPrecise

MabSilico

Myrio Therapeutics

Nona Biosciences

Rockland Immunochemicals

Synbio technologies

WuXi Biologics

Primary Research Overview

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders. The research report features detailed transcripts of interviews held with the following industry stakeholders:

Founder and President, Antibody Solutions

Chief Business Officer, Adimab

Vice President of Commercial Services, ImmunoPrecise Antibodies

Former Chief Executive Officer, Abveris

Founder and Chief Technology Officer, Nidus BioSciences

Former Chief Business Officer, AvantGen

Chief Executive Officer and Chief Scientific Officer, Single Cell Technology

Site Director, Distributed Bio

Co-Founder and Director of Emerging Science and Technology, AbCellera

Co-founder and Director, AbGenics Life Sciences

President and Chief Operating Officer, CDI Laboratories

Chief Executive Officer, AP Biosciences

Chief Executive Officer and General Manager, YUMAB

Business Development Manager, Antibody Solutions

Senior Vice President, Ligand Pharmaceuticals

Former Chief Scientific Officer, LakePharma

ANTIBODY DISCOVERY MARKET: RESEARCH COVERAGE

The report features an in-depth analysis of the antibody discovery market, focusing on key market segments, including type of service offered, antibody discovery method, type of antibody generated, nature of antibody generated, type of therapeutic areas and key geographical regions.

A comprehensive evaluation of over 160 service provides companies involved in antibody discovery services market, considering various parameters, such as year of establishment, company size, location of headquarters, type of service offered (antigen designing, hit generation, lead selection, and lead optimization and lead characterization), type of antibody discovery method (hybridoma based, library based, single cell based, transgenic animal based, and others), animal model used (rabbit, rat, mouse, llama, chicken, transgenic animal and others), type of antibody discovered (monoclonal antibody, bispecific antibody, single domain antibody, antibody drug conjugate, antibody fragment and others) and purpose of antibody discovery (therapeutic and diagnostic).

A comprehensive competitive analysis of antibody discovery service providers, examining factors such as years of experience, number of platforms, number of antibody discovery services offered, types of antibody discovery methods adopted, type of antibody formats generated, type of application areas. This analysis also presents the antibody discovery capabilities in different regions, based on a number of relevant parameters, such as type of service offered for service providers, and number of technologies offered, number of antibody discovery methods and type of antibody discovered by the platform providers.

In-depth profiles of key industry players that are actively engaged in providing antibody discovery services, focusing on company overviews, recent developments and an informed future outlook.

Thorough analysis of over 290 antibody discovery platforms, type of antibody discovered (monoclonal antibody, bispecific antibody, single domain antibody, antibody drug conjugate, antibody fragment and others), type of antibody discovery method (hybridoma based, library-based, single cell-based, transgenic animal-based, and others) and animal model used (rabbit, rat, mouse, llama, chicken, transgenic animal and others). In addition, it includes analysis of 190+ antibody discovery platform providers based on their company details such as year of establishment, company size and location of headquarters.

A comprehensive competitive analysis of antibody discovery technologies, examining factors such as supplier power and key specifications of the platforms, such as type of antibody discovered, compatibility of antibodies in human, number of deals signed for a particular platform (since 2015).

In-depth profiles of key industry players that are actively offering antibody discovery platform / technology to other companies, focusing on company overviews, antibody discovery platforms / technology, recent developments and an informed future outlook.

An analysis of partnerships established in this sector, since 2021, covering acquisitions, clinical trial agreements, mergers, multipurpose agreements, product / technology licensing agreements, product development and commercialization agreements, research and development agreements, service agreements, technology integration agreements, technology utilization agreements.

A detailed evaluation of the investments made in antibody discovery market, encompassing seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings.

An insightful deal structure analysis, highlighting cash flows and net present values of licensor and licensee, taking into consideration multiple likely scenarios of upfront, milestone and royalty payments.

A SWOT analysis of antibody humanization services focuses on identifying industry-specific trends, key market drivers and challenges faced by companies providing these services. This section also includes a comprehensive list of prominent players in the antibody humanization and affinity maturation market. Furthermore, it discusses the factors that are likely to impact the operations of firms involved in these services.

Detailed profiles of the most successful therapeutic monoclonal antibody products (as per sales reported in 2022). It provides detailed profiles on top five drugs, namely Humira®, Keytruda®, Stelara®, Opdivo® and Darzalex®, including information on their historical sales, discovery process and methods.

KEY QUESTIONS ANSWERED IN THIS REPORT

How many companies are currently engaged in this market?

Which are the leading companies in this market?

What kind of partnership models are commonly adopted by industry stakeholders?

What are the factors that are likely to influence the evolution of this market?

What is the current and future market size?

What is the CAGR of this market?

How is the current and future market opportunity likely to be distributed across key market segments?

REASONS TO BUY THIS REPORT

The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.

Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.

The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

ADDITIONAL BENEFITS

Complimentary PPT Insights Packs

Complimentary Excel Data Packs for all Analytical Modules in the Report

10% Free Content Customization

Detailed Report Walkthrough Session with Research Team

Free Updated report if the report is 6-12 months old or older